A Phase Ia/Ib, Open-Label, Multicenter study to evaluate the Safety, Pharmacokinetics, and activity of Ro7759065 as a single agent and in combination with ATEZOLIZUMAB in Patients with locally advanced or metastatic solid tumors

Inclusion Criteria: - Life expectancy at least 12 weeks - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Adequate hematologic and end-organ function - Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1 - Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy - Availability of representative tumor specimens required for patients in select cohorts. Exclusion Criteria: - Women who are pregnant or breastfeeding - Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment - Active hepatitis B or C or tuberculosis - Positive test for human immunodeficiency virus (HIV) infection - Acute or chronic active Epstein-Barr virus (EBV) infection at screening - Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7759065 infusion - Primary, untreated, or active central nervous system (CNS) metastases - Active or history of autoimmune disease or immune deficiency - Prior allogeneic stem cell or organ transplantation - Any history of a Grade 3 immune-mediated adverse event attributed to prior cancer immunotherapy that resulted in permanent discontinuation of that agent - Any history of a Grade 4 immune-mediated adverse event attributed to prior cancer immunotherapy.